title: Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.
abstract: OBJECTIVE
  We previously reported a 10% rate of catheter complications, including inflow obstruction and infection, using a fenestrated catheter to administer intraperitoneal (i.p.) chemotherapy for ovarian cancer. Because of recent reports of higher rates of catheter complications, we performed this study to update our experience with the fenestrated catheter.
  
  
  METHODS
  We reviewed the medical records of all patients who had a fenestrated catheter placed at our institution from 5/97-5/06. Data were collected regarding patient demographics, surgical procedure, timing of catheter insertion, and reasons for discontinuing i.p. chemotherapy.
  
  
  RESULTS
  We identified 342 patients who had fenestrated catheters placed and for whom follow-up data were available. Nine patients (3%) required discontinuation of chemotherapy due to catheter complications. Three patients experienced catheter infection, 5 patients had inflow obstruction, and 1 patient's port could not be accessed. Seventy-one patients (21%) discontinued i.p. chemotherapy for reasons unrelated to the catheter. The percentage of patients who completed the intended chemotherapy regimen was similar for patients who underwent a bowel resection (22/30 [73%]) compared to those who had not (226/312 [72%]) (P=1.0).
  
  
  CONCLUSIONS
  The fenestrated catheter for i.p. chemotherapy continues to be associated with a low risk of catheter-related complications. The low rate of complications, even in the setting of bowel resection and increase in utilization during upfront chemotherapy, suggest that the fenestrated catheter is still a feasible method for the administration of i.p. chemotherapy.
authors.affiliation: Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: Destin
authors.initials: D
authors.lastname: Black
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Levine
authors.forename: Linda
authors.initials: L
authors.lastname: Nicoll
authors.forename: Joanne F
authors.initials: JF
authors.lastname: Chou
authors.forename: Alexia
authors.initials: A
authors.lastname: Iasonos
authors.forename: Carol L
authors.initials: CL
authors.lastname: Brown
authors.forename: Yukio
authors.initials: Y
authors.lastname: Sonoda
authors.forename: Dennis S
authors.initials: DS
authors.lastname: Chi
authors.forename: Mario M
authors.initials: MM
authors.lastname: Leitao
authors.forename: Nadeem R
authors.initials: NR
authors.lastname: Abu-Rustum
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Ferguson
authors.forename: Richard R
authors.initials: RR
authors.lastname: Barakat
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002404:Catheterization / Q000009:adverse effects* / Q000379:methods; D002408:Catheters, Indwelling / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents